{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T02:41:00Z","timestamp":1789267260915,"version":"build-2803163510"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NIH","award":["R01 AI079031"],"award-info":[{"award-number":["R01 AI079031"]}]},{"name":"NIH","award":["R01 AI084817"],"award-info":[{"award-number":["R01 AI084817"]}]},{"name":"NIH","award":["R01 AI106005"],"award-info":[{"award-number":["R01 AI106005"]}]},{"DOI":"10.13039\/100011770","name":"Skaggs Institute for Chemical Biology at The Scripps Research Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011770","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.coviro.2015.04.001","type":"journal-article","created":{"date-parts":[[2015,4,29]],"date-time":"2015-04-29T00:46:38Z","timestamp":1430268398000},"page":"148-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design"],"prefix":"10.1016","volume":"11","author":[{"given":"Leopold","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli N","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansun","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2015.04.001_bib0705","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.coviro.2015.04.001_bib0710","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2015.04.001_bib0715","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","article-title":"Evolving epidemiology of hepatitis C virus","volume":"17","author":"Lavanchy","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.coviro.2015.04.001_bib0720","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2015.04.001_bib0725","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrgastro.2013.179","article-title":"HCV transmission in industrialized countries and resource-constrained areas","volume":"11","author":"Thursz","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.coviro.2015.04.001_bib0730","first-page":"SS-3","article-title":"Surveillance for acute viral hepatitis \u2014 United States, 2005","volume":"56","author":"CDC","year":"2007","journal-title":"MMWR"},{"key":"10.1016\/j.coviro.2015.04.001_bib0735","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-156-4-201202210-00004","article-title":"The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007","volume":"156","author":"Ly","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coviro.2015.04.001_bib0740","first-page":"517","article-title":"Use of enhanced surveillance for hepatitis C virus infection to detect a cluster among young injection-drug users \u2014 New York, November 2004\u2013April 2007","volume":"57","author":"Leuchner","year":"2008","journal-title":"MMWR"},{"key":"10.1016\/j.coviro.2015.04.001_bib0745","first-page":"537","article-title":"Hepatitis C virus infection among young adolescents and young adults \u2014 Massachusetts, 2002\u20132009","volume":"60","author":"CDC","year":"2011","journal-title":"MMWR"},{"key":"10.1016\/j.coviro.2015.04.001_bib0750","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.jhep.2014.09.006","article-title":"Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C","volume":"61","author":"Kumar","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2015.04.001_bib0755","doi-asserted-by":"crossref","first-page":"g3308","DOI":"10.1136\/bmj.g3308","article-title":"Antiviral treatment of hepatitis C","volume":"348","author":"Feeney","year":"2014","journal-title":"Br Med J"},{"key":"10.1016\/j.coviro.2015.04.001_bib0760","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/ajt.12714","article-title":"Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: \u201ca flood of opportunity\u201d","volume":"14","author":"Gane","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.coviro.2015.04.001_bib0765","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","article-title":"New hepatitis C therapies: the toolbox, strategies, and challenges","volume":"146","author":"Pawlotsky","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2015.04.001_bib0770","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/hep.23220","article-title":"Public health impact of antiviral therapy for hepatitis C in the United States","volume":"50","author":"Volk","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2015.04.001_bib0775","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.21927","article-title":"Predictors of treatment in patients with chronic hepatitis C infection \u2014 role of patient versus nonpatient factors","volume":"46","author":"Kanwal","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2015.04.001_bib0780","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1055\/s-0034-1371082","article-title":"Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas","volume":"34","author":"Lemoine","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.coviro.2015.04.001_sbref0785","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-59745-394-3_4","article-title":"Nomenclature and numbering of the hepatitis C virus","volume":"510","author":"Kuiken","year":"2009","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.coviro.2015.04.001_bib0790","doi-asserted-by":"crossref","first-page":"115ra111","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2015.04.001_sbref0795","doi-asserted-by":"crossref","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","article-title":"A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory","volume":"6","author":"Swadling","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2015.04.001_bib0800","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1016\/j.vaccine.2010.06.084","article-title":"Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults","volume":"28","author":"Frey","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2015.04.001_bib0805","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1086\/655902","article-title":"Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins","volume":"202","author":"Ray","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2015.04.001_bib0810","doi-asserted-by":"crossref","first-page":"e23699","DOI":"10.1371\/journal.pone.0023699","article-title":"A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection","volume":"6","author":"Meyer","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coviro.2015.04.001_bib0815","doi-asserted-by":"crossref","first-page":"e59776","DOI":"10.1371\/journal.pone.0059776","article-title":"A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1\/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans","volume":"8","author":"Law","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coviro.2015.04.001_bib0820","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1016\/j.vaccine.2007.08.053","article-title":"Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies","volume":"25","author":"Stamataki","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2015.04.001_bib0825","series-title":"Vaccines","first-page":"1187","article-title":"Hepatitis C virus vaccines","author":"Reali","year":"2008"},{"key":"10.1016\/j.coviro.2015.04.001_bib0830","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1073\/pnas.93.5.1759","article-title":"A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells","volume":"93","author":"Rosa","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.04.001_sbref0835","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge","volume":"14","author":"Law","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2015.04.001_bib0840","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1086\/339679","article-title":"Neutralization of pseudotyped vesicular stomatitis virus expressing hepatitis C virus envelope glycoprotein 1 or 2 by serum from patients","volume":"185","author":"Lagging","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2015.04.001_sbref0845","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20021756","article-title":"Infectious hepatitis C virus pseudo-particles containing functional E1\u2013E2 envelope protein complexes","volume":"197","author":"Bartosch","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2015.04.001_sbref0850","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1073\/pnas.0832180100","article-title":"Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles","volume":"100","author":"Hsu","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.04.001_sbref0855","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1073\/pnas.0503596102","article-title":"Robust hepatitis C virus infection in vitro","volume":"102","author":"Zhong","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.04.001_sbref0860","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1126\/science.1114016","article-title":"Complete replication of hepatitis C virus in cell culture","volume":"309","author":"Lindenbach","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.coviro.2015.04.001_sbref0865","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2015.04.001_sbref0870","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1073\/pnas.0510727103","article-title":"Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells","volume":"103","author":"Yi","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.04.001_sbref0875","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/90968","article-title":"Hepatitis C virus replication in mice with chimeric human livers","volume":"7","author":"Mercer","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2015.04.001_bib0880","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nbt1326","article-title":"Robust expansion of human hepatocytes in Fah(\u2212\/\u2212)\/Rag2(\u2212\/\u2212)\/Il2rg(\u2212\/\u2212) mice","volume":"25","author":"Azuma","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.coviro.2015.04.001_bib0885","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1172\/JCI40094","article-title":"Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment","volume":"120","author":"Bissig","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2015.04.001_sbref0890","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nature10168","article-title":"A genetically humanized mouse model for hepatitis C virus infection","volume":"474","author":"Dorner","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2015.04.001_bib0895","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2011.01.001","article-title":"A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease","volume":"140","author":"Washburn","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2015.04.001_bib0900","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature12427","article-title":"Completion of the entire hepatitis C virus life cycle in genetically humanized mice","volume":"501","author":"Dorner","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2015.04.001_sbref0905","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1073\/pnas.91.16.7792","article-title":"Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization","volume":"91","author":"Farci","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.04.001_bib0910","doi-asserted-by":"crossref","first-page":"15394","DOI":"10.1073\/pnas.93.26.15394","article-title":"Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein","volume":"93","author":"Farci","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.04.001_sbref0915","doi-asserted-by":"crossref","first-page":"7705","DOI":"10.1073\/pnas.0402458101","article-title":"Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma","volume":"101","author":"Yu","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.04.001_sbref0920","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1073\/pnas.91.4.1294","article-title":"Vaccination of chimpanzees against infection by the hepatitis C virus","volume":"91","author":"Choo","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.04.001_bib0925","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1128\/JVI.79.10.6023-6034.2005","article-title":"Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection","volume":"79","author":"Lavillette","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_sbref0930","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C","author":"Pestka","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.04.001_bib0935","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/hep.27013","article-title":"Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses","volume":"59","author":"Osburn","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2015.04.001_bib0940","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/lt.20876","article-title":"Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study","volume":"12","author":"Schiano","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.coviro.2015.04.001_bib0945","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jhep.2006.08.019","article-title":"Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity","volume":"46","author":"Galun","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2015.04.001_bib0950","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1086\/338266","article-title":"The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV","volume":"185","author":"Ilan","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2015.04.001_sbref0955","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1128\/JVI.80.6.2654-2664.2006","article-title":"Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients","volume":"80","author":"Eren","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib0960","doi-asserted-by":"crossref","first-page":"13783","DOI":"10.1128\/JVI.01091-07","article-title":"Human apolipoprotein E is required for infectivity and production of hepatitis C virus in cell culture","volume":"81","author":"Chang","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib0965","doi-asserted-by":"crossref","first-page":"10999","DOI":"10.1128\/JVI.00526-10","article-title":"Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture","volume":"84","author":"Gastaminza","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib0970","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.24523","article-title":"Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes","volume":"54","author":"Mazumdar","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2015.04.001_sbref0975","doi-asserted-by":"crossref","first-page":"9505","DOI":"10.1073\/pnas.1307527110","article-title":"Ultrastructural analysis of hepatitis C virus particles","volume":"110","author":"Catanese","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.04.001_bib0980","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00281-012-0356-2","article-title":"Lipids and HCV","volume":"35","author":"Bassendine","year":"2013","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.coviro.2015.04.001_bib0985","doi-asserted-by":"crossref","first-page":"18904","DOI":"10.1074\/jbc.M113.538256","article-title":"The association of hepatitis C virus glycoproteins with apolipoproteins E and B early in assembly is conserved in lipoviral particles","volume":"289","author":"Boyer","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2015.04.001_bib0990","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3390\/v6031149","article-title":"Incorporation of hepatitis C virus E1 and E2 glycoproteins: the keystones on a peculiar virion","volume":"6","author":"Vieyres","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2015.04.001_bib0995","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/hep.20906","article-title":"Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity","volume":"42","author":"Schofield","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2015.04.001_bib1000","doi-asserted-by":"crossref","first-page":"16269","DOI":"10.1073\/pnas.0705522104","article-title":"Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus","volume":"104","author":"Johansson","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.04.001_bib1005","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1128\/JVI.01872-07","article-title":"Isolation and characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus","volume":"82","author":"Meunier","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_sbref1010","doi-asserted-by":"crossref","first-page":"12473","DOI":"10.1128\/JVI.01138-09","article-title":"Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus","volume":"83","author":"Broering","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_sbref1015","doi-asserted-by":"crossref","first-page":"e1002653","DOI":"10.1371\/journal.ppat.1002653","article-title":"Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate","volume":"8","author":"Keck","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2015.04.001_sbref1020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/JVI.01941-12","article-title":"Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein","volume":"87","author":"Keck","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_sbref1025","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1114927109","article-title":"Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus","author":"Giang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.04.001_sbref1030","doi-asserted-by":"crossref","first-page":"e1002895","DOI":"10.1371\/journal.ppat.1002895","article-title":"Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees","volume":"8","author":"Morin","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2015.04.001_sbref1035","doi-asserted-by":"crossref","first-page":"254ra129","DOI":"10.1126\/scitranslmed.3009512","article-title":"Broadly neutralizing antibodies abrogate established hepatitis C virus infection","volume":"6","author":"de Jong","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2015.04.001_sbref1040","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/ajt.12083","article-title":"Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study","volume":"13","author":"Chung","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.coviro.2015.04.001_bib1045","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.3390\/v3112280","article-title":"Hepatitis C virus evasion mechanisms from neutralizing antibodies","volume":"3","author":"Di Lorenzo","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2015.04.001_bib1050","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.3390\/v3112127","article-title":"Neutralizing antibody response to hepatitis C virus","volume":"3","author":"Wang","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2015.04.001_bib1055","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.3390\/v4102016","article-title":"Neutralizing antibodies and pathogenesis of hepatitis C virus infection","volume":"4","author":"Fafi-Kremer","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2015.04.001_bib1060","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/jvh.12094","article-title":"Virus-neutralizing antibodies to hepatitis C virus","volume":"20","author":"Wahid","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.coviro.2015.04.001_bib1065","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fmicb.2014.00329","article-title":"Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies","volume":"5","author":"Drummer","year":"2014","journal-title":"Front Microbiol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2014.02.013","article-title":"The past, present and future of neutralizing antibodies for hepatitis C virus","author":"Ball","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2015.04.001_bib1075","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1128\/JVI.76.3.1181-1193.2002","article-title":"Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines","volume":"76","author":"Wellnitz","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1080","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1006\/viro.2002.1463","article-title":"Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding","volume":"298","author":"Triyatni","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2015.04.001_bib1085","doi-asserted-by":"crossref","first-page":"9224","DOI":"10.1128\/JVI.78.17.9224-9232.2004","article-title":"Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions","volume":"78","author":"Keck","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1090","doi-asserted-by":"crossref","first-page":"13199","DOI":"10.1128\/JVI.79.21.13199-13208.2005","article-title":"Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2","volume":"79","author":"Keck","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1095","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1128\/JVI.02475-07","article-title":"Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies","volume":"82","author":"Keck","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1100","first-page":"1","article-title":"Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies","volume":"317","author":"Keck","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1105","doi-asserted-by":"crossref","first-page":"e1004297","DOI":"10.1371\/journal.ppat.1004297","article-title":"Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412\u2013423","volume":"10","author":"Keck","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2015.04.001_bib1110","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00252-08","article-title":"A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope","author":"Keck","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1115","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1099\/vir.0.83386-0","article-title":"Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein","volume":"89","author":"Owsianka","year":"2008","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1120","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.bbapap.2007.12.015","article-title":"Structural elucidation of critical residues involved in binding of human monoclonal antibodies to hepatitis C virus E2 envelope glycoprotein","volume":"1784","author":"Iacob","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.coviro.2015.04.001_bib1125","doi-asserted-by":"crossref","first-page":"10451","DOI":"10.1128\/JVI.05259-11","article-title":"Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations","volume":"85","author":"Keck","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_sbref1130","doi-asserted-by":"crossref","first-page":"e1003364","DOI":"10.1371\/journal.ppat.1003364","article-title":"Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape","volume":"9","author":"Krey","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2015.04.001_sbref1135","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1126\/science.1243876","article-title":"Hepatitis C virus E2 envelope glycoprotein core structure","volume":"342","author":"Kong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.coviro.2015.04.001_sbref1140","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature13117","article-title":"Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2","volume":"509","author":"Khan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2015.04.001_bib1145","doi-asserted-by":"crossref","first-page":"8449","DOI":"10.1073\/pnas.0703039104","article-title":"Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma","volume":"104","author":"Zhang","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.04.001_bib1150","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1073\/pnas.0902749106","article-title":"Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity","volume":"106","author":"Zhang","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.04.001_bib1155","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2012.07.013","article-title":"Anti-hepatitis C virus E2 (HCV\/E2) glycoprotein monoclonal antibodies and neutralization interference","volume":"96","author":"Sautto","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2015.04.001_sbref1160","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1128\/JVI.06492-11","article-title":"Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus e2 protein confer noninterfering, additive neutralization","volume":"86","author":"Tarr","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1165","doi-asserted-by":"crossref","first-page":"11095","DOI":"10.1128\/JVI.79.17.11095-11104.2005","article-title":"Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein","volume":"79","author":"Owsianka","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_sbref1170","doi-asserted-by":"crossref","first-page":"9499","DOI":"10.1073\/pnas.1202924109","article-title":"Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1","volume":"109","author":"Kong","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.04.001_sbref1175","doi-asserted-by":"crossref","first-page":"13085","DOI":"10.1128\/JVI.01939-12","article-title":"Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33","volume":"86","author":"Kong","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_sbref1180","doi-asserted-by":"crossref","first-page":"12923","DOI":"10.1128\/JVI.02052-12","article-title":"Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody","volume":"86","author":"Potter","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1185","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.jmb.2013.02.025","article-title":"Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies","volume":"425","author":"Pantua","year":"2013","journal-title":"J Mol Biol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1190","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1099\/vir.0.83065-0","article-title":"Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33","volume":"88","author":"Tarr","year":"2007","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1195","doi-asserted-by":"crossref","first-page":"10459","DOI":"10.1128\/JVI.01584-14","article-title":"Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex","volume":"88","author":"Ruwona","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1200","doi-asserted-by":"crossref","first-page":"19450","DOI":"10.1073\/pnas.0809879105","article-title":"In vitro selection of a neutralization-resistant hepatitis C virus escape mutant","volume":"105","author":"Gal-Tanamy","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.04.001_bib1205","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1128\/JVI.02190-14","article-title":"Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein e2 recognized by broadly neutralizing antibodies","volume":"89","author":"Meola","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_sbref1210","article-title":"Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody","author":"Li","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2015.04.001_bib1215","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/hep.21088","article-title":"Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33","volume":"43","author":"Tarr","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2015.04.001_bib1220","doi-asserted-by":"crossref","first-page":"7418","DOI":"10.1073\/pnas.1305306110","article-title":"Structural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virus","volume":"110","author":"Deng","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.04.001_bib1225","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1099\/0022-1317-73-9-2313","article-title":"Expression and characterization of glycoprotein gp35 of hepatitis C virus using recombinant vaccinia virus","volume":"73","author":"Kohara","year":"1992","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1230","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/0140-6736(93)91983-S","article-title":"Persistence of HCV despite antibodies to both putative envelope glycoproteins","volume":"342","author":"Chien","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2015.04.001_bib1235","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/JVI.68.10.6147-6160.1994","article-title":"Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses","volume":"68","author":"Dubuisson","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1240","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1128\/JVI.78.13.7257-7263.2004","article-title":"Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity","volume":"78","author":"Keck","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1245","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1099\/0022-1317-80-4-887","article-title":"Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex","volume":"80","author":"Meunier","year":"1999","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1250","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.biolcel.2004.03.008","article-title":"Functional hepatitis C virus envelope glycoproteins","volume":"96","author":"Voisset","year":"2004","journal-title":"Biol Cell"},{"key":"10.1016\/j.coviro.2015.04.001_bib1255","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.virol.2004.11.034","article-title":"Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells","volume":"332","author":"Brazzoli","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2015.04.001_bib1260","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1099\/0022-1317-82-7-1629","article-title":"Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2","volume":"82","author":"Cocquerel","year":"2001","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1265","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1128\/JVI.71.1.697-704.1997","article-title":"Formation of native hepatitis C virus glycoprotein complexes","volume":"71","author":"Deleersnyder","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1270","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1006\/viro.2000.0693","article-title":"The transmembrane domain of the hepatitis C virus E2 glycoprotein is required for correct folding of the E1 glycoprotein and native complex formation","volume":"279","author":"Patel","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2015.04.001_bib1275","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1099\/0022-1317-78-9-2299","article-title":"Characterization of truncated forms of hepatitis C virus glycoproteins","volume":"78","author":"Michalak","year":"1997","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1280","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/JVI.74.2.702-709.2000","article-title":"Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein","volume":"74","author":"Flint","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1285","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1099\/0022-1317-81-12-2873","article-title":"Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding","volume":"81","author":"Patel","year":"2000","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1290","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.1128\/JVI.74.15.6885-6892.2000","article-title":"Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates","volume":"74","author":"Heile","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2005.12.027","article-title":"Cell entry of hepatitis C virus","volume":"348","author":"Bartosch","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2015.04.001_bib1300","doi-asserted-by":"crossref","first-page":"e1000762","DOI":"10.1371\/journal.ppat.1000762","article-title":"The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule","volume":"6","author":"Krey","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2015.04.001_bib1305","doi-asserted-by":"crossref","first-page":"11078","DOI":"10.1128\/JVI.00800-09","article-title":"Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain","volume":"83","author":"Whidby","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1310","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1128\/JVI.73.8.6782-6790.1999","article-title":"Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein","volume":"73","author":"Flint","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1315","doi-asserted-by":"crossref","first-page":"8752","DOI":"10.1128\/JVI.02642-06","article-title":"Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus","volume":"81","author":"Lavillette","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1320","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0042-6822(02)00065-X","article-title":"Proteomics computational analyses suggest that hepatitis C virus E1 and pestivirus E2 envelope glycoproteins are truncated class II fusion proteins","volume":"307","author":"Garry","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2015.04.001_bib1325","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1021\/bi0523963","article-title":"The membrane-active regions of the hepatitis C virus E1 and E2 envelope glycoproteins","volume":"45","author":"Perez-Berna","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.coviro.2015.04.001_bib1330","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1472-6807-9-48","article-title":"A computational approach identifies two regions of Hepatitis C Virus E1 protein as interacting domains involved in viral fusion process","volume":"9","author":"Bruni","year":"2009","journal-title":"BMC Struct Biol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1335","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1423-0127-16-89","article-title":"Mutagenesis of the fusion peptide-like domain of hepatitis C virus E1 glycoprotein: involvement in cell fusion and virus entry","volume":"16","author":"Li","year":"2009","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.coviro.2015.04.001_bib1340","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2174\/092986609788681779","article-title":"Conservation of hydrophobicity within viral envelope glycoproteins reveals a putative hepatitis C virus fusion peptide","volume":"16","author":"Taylor","year":"2009","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.coviro.2015.04.001_bib1345","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1365-2893.2009.01111.x","article-title":"Mutational analysis of the hepatitis C virus E1 glycoprotein in retroviral pseudoparticles and cell-culture-derived H77\/JFH1 chimeric infectious virus particles","volume":"16","author":"Russell","year":"2009","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.coviro.2015.04.001_bib1350","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.virol.2007.05.038","article-title":"Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles","volume":"367","author":"Yu","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2015.04.001_bib1355","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1099\/vir.0.82567-0","article-title":"Mutagenesis of a conserved fusion peptide-like motif and membrane-proximal heptad-repeat region of hepatitis C virus glycoprotein E1","volume":"88","author":"Drummer","year":"2007","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1360","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1107\/S139900471401339X","article-title":"Pushing the limits of sulfur SAD phasing: de novo structure solution of the N-terminal domain of the ectodomain of HCV E1","volume":"70","author":"El Omari","year":"2014","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.coviro.2015.04.001_sbref1365","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1038\/ncomms5874","article-title":"Unexpected structure for the N-terminal domain of hepatitis C virus envelope glycoprotein E1","volume":"5","author":"El Omari","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2015.04.001_bib1370","doi-asserted-by":"crossref","first-page":"31984","DOI":"10.1074\/jbc.M111.269605","article-title":"Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 contain reduced cysteine residues essential for virus entry","volume":"286","author":"Fraser","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2015.04.001_bib1375","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1128\/JVI.02659-12","article-title":"Disulfide bonds in hepatitis C virus glycoprotein E1 control the assembly and entry functions of E2 glycoprotein","volume":"87","author":"Wahid","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1380","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nbt.2197","article-title":"B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study","volume":"30","author":"Haynes","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.coviro.2015.04.001_bib1385","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.chom.2012.09.008","article-title":"A blueprint for HIV vaccine discovery","volume":"12","author":"Burton","year":"2012","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2015.04.001_bib1390","doi-asserted-by":"crossref","first-page":"1232910","DOI":"10.1126\/science.1232910","article-title":"Accelerating next-generation vaccine development for global disease prevention","volume":"340","author":"Koff","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.coviro.2015.04.001_bib1395","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMra1204186","article-title":"Designing tomorrow's vaccines","volume":"368","author":"Nabel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2015.04.001_bib1400","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"Jardine","year":"2013","journal-title":"Science"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625715000504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625715000504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T12:54:21Z","timestamp":1598964861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625715000504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":140,"alternative-id":["S1879625715000504"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2015.04.001","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2015.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}